Back to Search
Start Over
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
- Source :
- JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante, instname, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Publication Year :
- 2021
- Publisher :
- Oxford University Press, 2021.
-
Abstract
- Background The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309–0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274–0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092–2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
- Subjects :
- Male
Aging
medicine.medical_specialty
Multivariate analysis
Age ≥ 80
Coronavirus disease-2019
Type 2 diabetes
Logistic regression
AcademicSubjects/MED00280
Angiotensin Receptor Antagonists
Diabetes mellitus
Internal medicine
medicine
Humans
Hypoglycemic Agents
Hospital Mortality
Mortality
cardiometabolic therapy
Aged, 80 and over
Dipeptidyl-Peptidase IV Inhibitors
age ≥80
business.industry
SARS-CoV-2
coronavirus disease-2019
Type 2 Diabetes Mellitus
COVID-19
Age = 80
Odds ratio
medicine.disease
mortality
Confidence interval
Hospitalization
Cardiometabolic therapy
Diabetes Mellitus, Type 2
Cardiovascular Diseases
AcademicSubjects/SCI00960
Observational study
Female
type 2 diabetes
Geriatrics and Gerontology
business
Research Article
Subjects
Details
- ISSN :
- 10795006
- Database :
- OpenAIRE
- Journal :
- JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante, instname, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Accession number :
- edsair.doi.dedup.....609e7b999c26dd329fbdaebaa3447cbf